EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial

Kuan Ken Lee, Dimitrios Doudesis, Amy V Ferry, Andrew R Chapman, Dorien M Kimenai, Takeshi Fujisawa, Anda Bularga, Matthew T H Lowry, Caelan Taggart, Stacey Schulberg, Ryan Wereski, Chris Tuck und 6 weitere

BMJ · 27.11.2023 · 383 · e075009

DOI: 10.1136/bmj-2023-075009 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BMJ, online erschienen am 27.11.2023. Verfasst von Kuan Ken Lee und 17 weiteren Autor:innen. Beteiligte Einrichtung: British Heart Foundation (BHF) Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SA, UK. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Myocardial Infarction. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the impact of implementing a high sensitivity assay for cardiac troponin I on long term outcomes in patients with suspected acute coronary syndrome.

Design

Secondary observational analysis of a stepped wedge, cluster randomised controlled trial.

Setting

10 secondary and tertiary care centres in Scotland, UK.

Participants

48 282 consecutive patients with suspected acute coronary syndrome. Myocardial injury was defined as any high sensitivity assay result for cardiac troponin I >99th centile of 16 ng/L in women and 34 ng/L in men.

Intervention

Hospital sites were randomly allocated to either early (n=5 hospitals) or late (n=5 hospitals) implementation of a high sensitivity cardiac troponin I assay with sex specific diagnostic thresholds. Main outcome measure The main outcome was myocardial infarction or death at five years.

Results

10 360 patients had cardiac troponin concentrations greater than the 99th centile, of whom 1771 (17.1%) were reclassified by the high sensitivity assay. The five year incidence of subsequent myocardial infarction or death before and after implementation of the high sensitivity assay was 29.4% (5588/18 978) v 25.9% (7591/29 304), respectively, in all patients (adjusted hazard ratio 0.97, 95% confidence interval 0.93 to 1.01), and 63.0% (456/720) v 53.9% (567/1051), respectively, in those reclassified by the high sensitivity assay (0.82, 0.72 to 0.94). After implementation of the high sensitivity assay, a reduction in subsequent myocardial infarction or death was observed in patients with non-ischaemic myocardial injury (0.83, 0.75 to 0.91) but not in those with type 1 or type 2 myocardial infarction (0.92, 0.83 to 1.01 and 0.98, 0.84 to 1.14).

Conclusions

Implementation of a high sensitivity cardiac troponin I assay in the assessment of patients with suspected acute coronary syndrome was associated with a reduced risk of subsequent myocardial infarction or death at five years in those reclassified by the high sensitivity assay. Improvements in outcome were greatest in patients with non-ischaemic myocardial injury, suggesting a broader benefit beyond the identification of myocardial infarction.

Trial registration

ClinicalTrials.gov NCT01852123 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeMyocardial InfarctionMaleHumansFemaleTroponin IRisk AssessmentScotlandBiomarkers

Substanzen

Troponin IBiomarkers

Autor:innen und Institutionen

  • British Heart Foundation (BHF) Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SA, UK.
  • Usher Institute, University of Edinburgh, Edinburgh, UK.
  • London School of Hygiene and Tropical Medicine, London, UK.
  • British Heart Foundation (BHF) Centre for Cardiovascular Science, University of Edinburgh, Edinburgh EH16 4SA, UK nick.mills@ed.ac.uk.

ORCID-Profile: Nicholas L Mills

Förderung

  • British Heart Foundation
  • Medical Research Council

Zitieren

APA

Lee, K. K., Doudesis, D., Ferry, A. V., Chapman, A. R., Kimenai, D. M., Fujisawa, T., Bularga, A., Lowry, M. T. H., Taggart, C., Schulberg, S., Wereski, R., Tuck, C., Strachan, F. E., Newby, D. E., Anand, A., Shah, A. S. V., Mills, N. L., & High-STEACS Investigators (2023). Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial. BMJ, 383, e075009. https://doi.org/10.1136/bmj-2023-075009

Vancouver

Lee KK, Doudesis D, Ferry AV, Chapman AR, Kimenai DM, Fujisawa T, et al. Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial. BMJ. 2023;383:e075009. doi:10.1136/bmj-2023-075009

BibTeX
@article{Lee2023,
  author = {Lee, Kuan Ken and Doudesis, Dimitrios and Ferry, Amy V and Chapman, Andrew R and Kimenai, Dorien M and Fujisawa, Takeshi and Bularga, Anda and Lowry, Matthew T H and Taggart, Caelan and Schulberg, Stacey and Wereski, Ryan and Tuck, Chris and Strachan, Fiona E and Newby, David E and Anand, Atul and Shah, Anoop S V and Mills, Nicholas L and High-STEACS Investigators, High-STEACS Investigators},
  title = {Implementation of a high sensitivity cardiac troponin I assay and risk of myocardial infarction or death at five years: observational analysis of a stepped wedge, cluster randomised controlled trial},
  journal = {BMJ},
  year = {2023},
  volume = {383},
  pages = {e075009},
  doi = {10.1136/bmj-2023-075009}
}
Kostenlos starten →